Chronic exposure to PM2.5 is associated with increased risk of developing AD, with variation across demographic characteristics.
Topline data were announced from a phase 3 trial evaluating dexpramipexole as an add-on therapy in patients with eosinophilic asthma.
The FDA has approved updated prescribing information for Airsupra to include the BATURA study in patients with mild asthma.
A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback